Cargando…

Anticancer efficacy of hirsuteine against colorectal cancer by opposite modulation of wild-type and mutant p53

PURPOSE: The present study aimed to explore the anticancer activity of hirsuteine (HST), an indole alkaloid from the traditional Chinese herbal medicine Uncaria rhynchophylla, against colorectal cancer (CRC) and the underlining mechanism. METHODS: MTT, colony formation, flow cytometry and MDC staini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yan, Guo, Tingting, Li, Shurong, Ren, Zehao, Gao, Shan, Lu, Hao, Ma, Xuelan, Liu, Donghui, Liu, Yao, Kong, Dexin, Qiu, Yuling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232392/ https://www.ncbi.nlm.nih.gov/pubmed/37256374 http://dx.doi.org/10.1007/s12672-023-00688-1

Ejemplares similares

Growth Inhibitory and Pro-Apoptotic Effects of Hirsuteine in Chronic Myeloid Leukemia Cells through Targeting Sphingosine Kinase 1
por: Gao, Shan, et al.
Publicado: (2022)

Inhibitory effect and mechanism of hirsuteine on NCI‑H1299 lung cancer cell lines
por: Yun, Xuelin, et al.
Publicado: (2023)

Effects of hirsuteine on MDA-MB-453 breast cancer cell proliferation
por: Meng, Jie, et al.
Publicado: (2022)

Tissue Distribution of Hirsutine and Hirsuteine in Mice by Ultrahigh-Performance Liquid Chromatography-Mass Spectrometry
por: Zhou, Quan, et al.
Publicado: (2020)

Identification of anticancer drugs to radiosensitise BRAF-wild-type and mutant colorectal cancer
por: Carter, Rebecca, et al.
Publicado: (2019)

Reactivation of wild-type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule
por: Soares, Joana, et al.
Publicado: (2015)

Anticancer effect of Indanone-based thiazolyl hydrazone derivative on p53 mutant colorectal cancer cell lines: An in vitro and in vivo study
por: Narayanan, Silpa, et al.
Publicado: (2022)

Wild type p53 function in p53(Y220C) mutant harboring cells by treatment with Ashwagandha derived anticancer withanolides: bioinformatics and experimental evidence
por: Sundar, Durai, et al.
Publicado: (2019)

Editorial: Advances in wild type and mutant p53 research in cancer
por: Hernández-de la Cruz, Olga N., et al.
Publicado: (2022)

The Inhibition of Autophagy Sensitises Colon Cancer Cells with Wild-Type p53 but Not Mutant p53 to Topotecan Treatment
por: Li, Dan-Dan, et al.
Publicado: (2012)

Noncanonical DNA Motifs as Transactivation Targets by Wild Type and Mutant p53
por: Jordan, Jennifer J., et al.
Publicado: (2008)

Maspin subcellular expression in wild-type and mutant TP53 gastric cancers
por: Gurzu, Simona, et al.
Publicado: (2020)

Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer
por: Zhang, Shengliang, et al.
Publicado: (2022)

Berberine Inhibits Cell Proliferation by Interfering with Wild-Type and Mutant P53 in Human Glioma Cells
por: Liu, Ziqiang, et al.
Publicado: (2020)

Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy
por: Zhao, Wennan, et al.
Publicado: (2017)

Molecular Dynamics Simulations of Wild Type and Mutants of SAPAP in Complexed with Shank3
por: Piao, Lianhua, et al.
Publicado: (2019)

Correction: Noncanonical DNA Motifs as Transactivation Targets by Wild Type and Mutant p53
por: Jordan, Jennifer J., et al.
Publicado: (2008)

Temperature sensitivity of human wild-type and mutant p53 proteins expressed in vivo.
por: Ponchel, F., et al.
Publicado: (1998)

Correction: Noncanonical DNA Motifs as Transactivation Targets by Wild Type and Mutant p53
por: Jordan, Jennifer J., et al.
Publicado: (2008)

Chemokine Network and Overall Survival in TP53 Wild-Type and Mutant Ovarian Cancer
por: Ignacio, Rosa Mistica C., et al.
Publicado: (2018)

Mutant and Wild-Type Tumor Suppressor p53 Induces p300 Autoacetylation
por: Kaypee, Stephanie, et al.
Publicado: (2018)

Recent findings on the role of wild-type and mutant p53 in cancer development and therapy
por: Babamohamadi, Mehregan, et al.
Publicado: (2022)

Opposing Roles of Wild-type and Mutant p53 in the Process of Epithelial to Mesenchymal Transition
por: Semenov, Oleg, et al.
Publicado: (2022)

Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1
por: Bollu, Lakshmi Reddy, et al.
Publicado: (2020)

Wild-type p53 oligomerizes more efficiently than p53 hot-spot mutants and overcomes mutant p53 gain-of-function via a “dominant-positive” mechanism
por: Walerych, Dawid, et al.
Publicado: (2018)

Selective synergistic anticancer effects of cisplatin and oridonin against human p53-mutant esophageal squamous carcinoma cells
por: Yang, Huiyu, et al.
Publicado: (2021)

Therapy of murine tumors with p53 wild-type and mutant sequence peptide- based vaccines
Publicado: (1996)

Kevetrin induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells
por: Napolitano, Roberta, et al.
Publicado: (2020)

Redox Sensitive Cysteine Residues as Crucial Regulators of Wild-Type and Mutant p53 Isoforms
por: Butturini, Elena, et al.
Publicado: (2021)

A sheep in wolf's clothing? Wild-type P53 disguises as mutant to promote leukemogenesis
por: Ferris, Margaret A., et al.
Publicado: (2022)

The Competition of Yin and Yang: Exploring the Role of Wild-Type and Mutant p53 in Tumor Progression
por: Cai, Bi-He, et al.
Publicado: (2023)

Wild-type and mutant p53 in cancer-related ferroptosis. A matter of stress management?
por: Corazzari, Marco, et al.
Publicado: (2023)

Secreted calreticulin mutants subvert anticancer immunosurveillance
por: Liu, Peng, et al.
Publicado: (2019)

Neuroprotective effect of chondroitin sulfate on SH-SY5Y cells overexpressing wild-type or A53T mutant α-synuclein
por: Ju, Chuanxia, et al.
Publicado: (2017)

Mutant p53 Cooperates with Knockdown of Endogenous Wild-Type p53 to Disrupt Tubulogenesis in Madin-Darby Canine Kidney Cells
por: Zhang, Yanhong, et al.
Publicado: (2013)

Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties
por: Nakayama, Mizuho, et al.
Publicado: (2020)

The anticancer effect of saffron in two p53 isogenic colorectal cancer cell lines
por: Bajbouj, Khuloud, et al.
Publicado: (2012)

Increased serum levels of mutant p53 proteins in patients with colorectal cancer.
por: Shim, K. S., et al.
Publicado: (1998)

Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors
por: Li, Hui, et al.
Publicado: (2019)

Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell Lines
por: Davidson, Brittany Anne, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0plqvpfqcdah5ibibsl2prvc32